Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ERN1 | O75460 | 7/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | TSHR | P16473 | 1/20 | 0.38 |
| ▸ | KCNJ1 | P48048 | 3/20 | 0.38 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.35 |
| ▸ | MEN1 | O00255 | 1/20 | 0.35 |
| ▸ | LMNA | P02545 | 1/20 | 0.35 |
| ▸ | THRB | P10828 | 1/20 | 0.35 |
| ▸ | BLM | P54132 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.33 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.33 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.33 |
| ▸ | CES2 | O00748 | 1/20 | 0.32 |
| ▸ | CES1 | P23141 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5232154 | 0.84 | ERN1 (0.43) | ERN1ALDH1A1TSHRKCNJ1TDP1 | |
| SCHEMBL9712525 | 0.83 | TDP1 (0.42) | ERN1ALDH1A1TSHRKCNJ1TDP1 | |
| SCHEMBL5233407 | 0.82 | ALDH1A1 (0.43) | ERN1ALDH1A1TSHRKCNJ1TDP1 | |
| SCHEMBL584614 | 0.82 | ERN1 (0.42) | ERN1ALDH1A1TSHRKCNJ1TDP1 | |
| SCHEMBL3714181 | 0.79 | HDAC4 (0.31) | HDAC4 | |
| SCHEMBL23065826 | 0.78 | ERN1 (0.39) | ERN1ALDH1A1TSHRKCNJ1TDP1 | |
| SCHEMBL10290090 | 0.78 | ERN1 (0.39) | ERN1ALDH1A1TSHRKCNJ1TDP1 | |
| SCHEMBL19948618 | 0.78 | ERN1 (0.39) | ERN1ALDH1A1TSHRKCNJ1TDP1 | |
| SCHEMBL21121085 | 0.78 | TDP1 (0.42) | ERN1ALDH1A1TSHRKCNJ1TDP1 | |
| SCHEMBL18685382 | 0.78 | TDP1 (0.42) | ERN1ALDH1A1TSHRKCNJ1TDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 85 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-111808069-B | Preparation method of baroxavir key intermediate and intermediate thereof | 中国药科大学 | 2022-05-17 | — | — | CN | claimed |
| CN-111808069-A | Preparation method of baroxavir key intermediate and intermediate thereof | 中国药科大学 | 2020-10-23 | — | — | CN | claimed |
| US-12351575-B2 | 6-fused heteroaryldihydropyrimidines for the treatment and prophylaxis of hepatitis B virus infection | HOFFMANN-LA ROCHE INC. (US) | 2025-07-08 | — | — | US | disclosed |
| EP-3928836-B1 | N-SUBSTITUTED INDOLE DERIVATIVES AS PGE2 RECEPTOR MODULATORS | IDORSIA PHARMACEUTICALS LTD (CH) | 2024-09-18 | — | — | EP | disclosed |
| US-12011444-B2 | N-substituted indole derivatives as PGE2 receptor modulators | IDORSIA PHARMACEUTICALS LTD (CH) | 2024-06-18 | — | — | US | disclosed |
| US-20240166649-A1 | DIHYDROPYRIMIDINE COMPOUND, PREPARATION METHOD THEREFOR AND APPLICATION THEREOF | SHANGHAI VISONPHARMA CO., LTD. (CN) | 2024-05-23 | — | — | US | disclosed |
| EP-4293022-A1 | DIHYDROPYRIMIDINE COMPOUND, PREPARATION METHOD THEREFOR AND APPLICATION THEREOF | Shanghai Visonpharma Co., Ltd. (CN) | 2023-12-20 | — | — | EP | disclosed |
| CN-115210237-B | Dihydropyrimidine compound, preparation method and application thereof | 上海维申医药有限公司 | 2023-11-14 | — | — | CN | disclosed |
| CN-115003673-B | Dihydropyrimidine compound, preparation method and application thereof | 上海维申医药有限公司 | 2023-08-11 | — | — | CN | disclosed |
| US-20230165865-A1 | HETEROARYLDIHYDROPYRIMIDINE DERIVATIVES AND METHODS OF TREATING HEPATITIS B INFECTIONS | JANSSEN PHARMACEUTICA NV (BE) | 2023-06-01 | — | — | US | disclosed |
| US-11639350-B2 | Heteroaryldihydropyrimidine derivatives and methods of treating hepatitis B infections | JANSSEN PHARMACEUTICA NV (BE) | 2023-05-02 | — | — | US | disclosed |
| US-8541449-B2 | Substituted isoquinolines and isoquinolinones as Rho kinase inhibitors | SANOFI (FR) | 2013-09-24 | — | — | US | disclosed |
| EP-2313374-B1 | 6-SUBSTITUTED ISOQUINOLINES AND ISOQUINOLINONES | SANOFI SA (FR) | 2013-09-18 | — | — | EP | disclosed |
| US-20130109715-A1 | 6-Substituted isoquinolines and isoquinolinones | SANOFI (FR) | 2013-05-02 | — | — | US | disclosed |
| US-8399482-B2 | 6-substituted isoquinolines and isoquinolinones | SANOFI (FR) | 2013-03-19 | — | — | US | disclosed |
| WO-2009156100-A1 | SUBSTITUTED ISOQUINOLINES AND ISOQUINOLINONES AS RHO KINASE INHIBITORS | SANOFI-AVENTIS (FR) | 2009-12-30 | — | — | WO | disclosed |
| WO-2009156099-A1 | 6-SUBSTITUTED ISOQUINOLINES AND ISOQUINOLINONES | SANOFI-AVENTIS (FR) | 2009-12-30 | — | — | WO | disclosed |
| EP-1514864-B1 | Difluoralkyl aromatic compounds | SALTIGO GMBH (DE) | 2008-03-19 | — | — | EP | disclosed |
| EP-1514864-A2 | Difluoralkyl aromatic compounds | Bayer Chemicals AG (DE) | 2005-03-16 | — | — | EP | disclosed |
| US-20050054733-A1 | Difluoroalkylaromatics | LANXESS DEUTSCHLAND GMBH (DE) | 2005-03-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230165865-A1 | HETEROARYLDIHYDROPYRIMIDINE DERIVATIVES AND METHODS OF TREATING HEPATITIS B INFECTIONS | HAVCR2, HCCS, PYGL | ERN1 2629/4885ALDH1A1 1615/4885TSHR 4103/4885 |
| US-12011444-B2 | N-substituted indole derivatives as PGE2 receptor modulators | PTGER1, PTGER4, PTGER2 | ERN1 1755/4885ALDH1A1 761/4885TSHR 325/4885 |
| US-20130109715-A1 | 6-Substituted isoquinolines and isoquinolinones | MYLK2, MYLK, MYLK3 | ERN1 2562/4885ALDH1A1 2500/4885TSHR 4168/4885 |
| US-12351575-B2 | 6-fused heteroaryldihydropyrimidines for the treatment and prophylaxis of hepatitis B virus infection | DPYD, CYP2D6, CYP2B6 | ERN1 2275/4885ALDH1A1 1133/4885TSHR 1928/4885 |
| US-20240166649-A1 | DIHYDROPYRIMIDINE COMPOUND, PREPARATION METHOD THEREFOR AND APPLICATION THEREOF | DPYD, GOT1, WEE1 | ERN1 4198/4885ALDH1A1 623/4885TSHR 4834/4885 |
| US-20050054733-A1 | Difluoroalkylaromatics | NQO1, TYR, FLI1 | ERN1 3643/4885ALDH1A1 393/4885TSHR 4783/4885 |
| US-11639350-B2 | Heteroaryldihydropyrimidine derivatives and methods of treating hepatitis B infections | HCCS, HAVCR2, NR1H4 | ERN1 2487/4885ALDH1A1 1584/4885TSHR 3525/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.